SCI时时刷

search
+
Personalizing adjuvant therapy for patients with colorectal cancer
Personalizing adjuvant therapy for patients with colorectal cancer
The current standard-of-care adjuvant treatment for patients with colorectal cancer (CRC) comprises a fluoropyrim...
Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients
Neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy with pelvic lymphadenectomy is the cur...
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell malignancies or relapsed and/or...
From the ESMO Congress 2023
As in 2017, this year’s ESMO Congress brought many members of the oncology community together in Madrid, this time with &g...
Computational immunogenomic approaches to predict response to cancer immunotherapies
Computational immunogenomic approaches to predict response to cancer immunotherapies
Cancer immunogenomics is an emerging field that bridges genomics and immunology. The establishment of large-scale genomic ...
THOR provides new data on the efficacy of erdafitinib
The outcomes of patients with metastatic urothelial carcinoma (mUC) and non-muscle invasive urothelial carcinoma (NMIBC) f...
Activity of selpercatinib confirmed in phase III trials
In May 2020, the FDA granted Accelerated Approval to the RET kinase inhibitor selpercatinib for patients with metastatic n...
From ESMO 2023: advances in lung cancer
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obta...
From CHRYSALIS to PAPILLON: the metamorphosis of amivantamab into frontline therapy for NSCLC
In 2021, data from the phase I CHRYSALIS trial supported the FDA Accelerated Approval of amivantamab, an EGFR–MET bispecif...
Progress in systemic therapy for advanced-stage urothelial carcinoma
Progress in systemic therapy for advanced-stage urothelial carcinoma
Despite recent advances, advanced-stage urothelial carcinoma (aUC) remains incurable, with 5-year survival rates of approx...
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs
Projected increases of cancer-attributable health-care costs, accompanied by staff shortages, will impose future economic ...
Molecular tumour boards — current and future considerations for precision oncology
Molecular tumour boards — current and future considerations for precision oncology
Over the past 15 years, rapid progress has been made in developmental therapeutics, especially regarding the use of matche...
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed
Composite outcome measures such as progression-free survival and disease-free survival are increasingly used as surrogate ...
Heterogeneity and treatment landscape of ovarian carcinoma
Heterogeneity and treatment landscape of ovarian carcinoma
Ovarian carcinoma is characterized by heterogeneity at the molecular, cellular and anatomical levels, both spatially and t...
Nasopharyngeal cancer screening with an anti-BNLF2b antibody: a new arrow in the quiver?
Epstein–Barr virus (EBV)-based biomarkers are used for nasopharyngeal carcinoma (NPC) screening in endemic regions. ...
Irradiation of asymptomatic bone metastases improves outcomes
Bone metastases are associated with considerable morbidity, and radiotherapy is widely used for palliation of symptomatic ...
Dabrafenib–trametinib moves to the first line in low-grade glioma
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obta...
Dabrafenib–trametinib is effective in paediatric high-grade glioma
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obta...
Biomarkers for immunotherapy of hepatocellular carcinoma
Biomarkers for immunotherapy of hepatocellular carcinoma
Immune-checkpoint inhibitors (ICIs) are now widely used for the treatment of patients with advanced-stage hepatocellular c...
Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma
In 2023, a decade after granting Accelerated Approval to the first-in-class BTK inhibitor ibrutinib for the treatment of m...
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC
Patients with advanced-stage EGFR-mutant non-small-cell lung cancer (NSCLC) usually receive an EGFR-targeted therapy, foll...
Drug-tolerant persister cells in cancer: the cutting edges and future directions
Drug-tolerant persister cells in cancer: the cutting edges and future directions
Drug-tolerant persister (DTP) cell populations were originally discovered in antibiotic-resistant bacterial biofilms. Simi...
Early promising results with the novel KRASG12C inhibitor divarasib
Early promising results with the novel KRASG12C inhibitor divarasib
Over the past few years, several studies have demonstrated the efficacy of sotorasib and adagrasib in patients with KRASG1...
Sacituzumab govitecan improves OS in heavily pretreated patients
Patients with advanced-stage HR+, HER2– breast cancer and disease progression on endocrine therapy plus a targeted therapy...
Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma
Following the recent FDA Accelerated Approval of enfortumab vedotin (EV) plus pembrolizumab for patients with advanced-sta...
TAM family kinases as therapeutic targets at the interface of cancer and immunity
TAM family kinases as therapeutic targets at the interface of cancer and immunity
Novel treatment approaches are needed to overcome innate and acquired mechanisms of resistance to current anticancer thera...
Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects
Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects
Harnessing mRNA–lipid nanoparticles (LNPs) to treat patients with cancer has been an ongoing research area that star...
Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer
Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer
The improved survival outcomes of patients with non-small-cell lung cancer (NSCLC), largely owing to the improved control ...
Novel ICI–TKI combination improves HCC outcomes
Historically, therapy for advanced-stage hepatocellular carcinoma (HCC) was almost entirely dependent on VEGFR-directed mu...
Adjuvant nivolumab shows promise in MCC
Merkel cell carcinoma (MCC) is a rare but highly aggressive skin cancer, with recurrence rates of 27–77% after surgery wit...
阅读更多
format_indent_increase